27516476|t|Improved adipose tissue function with initiation of protease inhibitor - only ART
27516476|a|Use of ART containing HIV PIs has previously been associated with toxicity in subcutaneous adipose tissue (SAT), potentially contributing to the development of lipodystrophy and insulin resistance. However, the effect of PIs on SAT function in ART - naive patients independent of other ART classes is unknown. This study aimed to elucidate the effect of initiating PI - only ART on SAT function in ART - naive subjects. In the HIVNAT-019 study, 48 HIV-infected, ART - naive Thai adults commencing PI - only ART comprising lopinavir / ritonavir / saquinavir for 24 weeks underwent assessments of fasting metabolic parameters and body composition. In a molecular substudy, 20 subjects underwent SAT biopsies at weeks 0, 2 and 24 for transcriptional, protein, mitochondrial DNA (mtDNA) and histological analyses. ClinicalTrials.gov registration number: NCT00400738. Over 24 weeks, limb fat increased (+416.4 g, P = 0.023), coinciding with larger adipocytes as indicated by decreased adipocyte density in biopsies (-32.3 cells /mm(2), P = 0.047) and increased mRNA expression of adipogenesis regulator PPARG at week 2 (+58.1%, P = 0.003). Increases in mtDNA over 24 weeks (+600 copies/cell, P = 0.041), decreased NRF1 mRNA expression at week 2 (-33.7%, P < 0.001) and increased COX2 / COX4 protein ratio at week 24 (+288%, P = 0.038) indicated improved mitochondrial function. Despite decreased AKT2 mRNA at week 2 (-28.6%, P = 0.002) and increased PTPN1 mRNA at week 24 (+50.3%, P = 0.016) suggesting insulin resistance, clinical insulin sensitivity [by homeostasis model assessment (HOMA-IR)] was unchanged. Initiation of PI - only ART showed little evidence of SAT toxicity, the changes observed being consistent with a return to health rather than contributing to lipodystrophy. icle
27516476	9	23	adipose tissue	T017	UMLS:C0001527
27516476	52	70	protease inhibitor	T103	UMLS:C0033607
27516476	78	81	ART	T058	UMLS:C1963724
27516476	89	92	ART	T058	UMLS:C1963724
27516476	89	92	ART	T058	UMLS:C1963724
27516476	104	111	HIV PIs	T103	UMLS:C3536912
27516476	148	156	toxicity	T037	UMLS:C0600688
27516476	160	187	subcutaneous adipose tissue	T017	UMLS:C0222331
27516476	189	192	SAT	T017	UMLS:C0222331
27516476	242	255	lipodystrophy	T038	UMLS:C0023787
27516476	260	278	insulin resistance	T038	UMLS:C0021655
27516476	303	306	PIs	T103	UMLS:C0033607
27516476	303	306	PIs	T103	UMLS:C0033607
27516476	310	313	SAT	T017	UMLS:C0222331
27516476	326	329	ART	T058	UMLS:C1963724
27516476	332	337	naive	T201	UMLS:C0919936
27516476	368	371	ART	T058	UMLS:C1963724
27516476	447	449	PI	T103	UMLS:C0033607
27516476	457	460	ART	T058	UMLS:C1963724
27516476	464	467	SAT	T017	UMLS:C0222331
27516476	480	483	ART	T058	UMLS:C1963724
27516476	486	491	naive	T201	UMLS:C0919936
27516476	509	525	HIVNAT-019 study	T062	UMLS:C0242481
27516476	530	542	HIV-infected	T038	UMLS:C0019693
27516476	544	547	ART	T058	UMLS:C1963724
27516476	550	555	naive	T201	UMLS:C0919936
27516476	556	560	Thai	T098	UMLS:C0337910
27516476	579	581	PI	T103	UMLS:C0033607
27516476	589	592	ART	T058	UMLS:C1963724
27516476	604	613	lopinavir	T103	UMLS:C0674432
27516476	616	625	ritonavir	T103	UMLS:C0292818
27516476	628	638	saquinavir	T103	UMLS:C0286738
27516476	662	673	assessments	T058	UMLS:C1261322
27516476	677	684	fasting	T033	UMLS:C0015663
27516476	685	694	metabolic	T038	UMLS:C0025519
27516476	743	751	substudy	T170	UMLS:C4288169
27516476	775	778	SAT	T017	UMLS:C0222331
27516476	779	787	biopsies	T058	UMLS:C0005558
27516476	813	828	transcriptional	T038	UMLS:C0040649
27516476	830	837	protein	T062	UMLS:C1514534
27516476	839	856	mitochondrial DNA	T103	UMLS:C0012929
27516476	858	863	mtDNA	T103	UMLS:C0012929
27516476	869	890	histological analyses	T058	UMLS:C0344441
27516476	892	943	ClinicalTrials.gov registration number: NCT00400738	T062	UMLS:C0008976
27516476	960	978	limb fat increased	T033	UMLS:C0243095
27516476	1025	1035	adipocytes	T017	UMLS:C0206131
27516476	1039	1048	indicated	T033	UMLS:C1444656
27516476	1062	1071	adipocyte	T017	UMLS:C0206131
27516476	1083	1091	biopsies	T058	UMLS:C0005558
27516476	1099	1104	cells	T017	UMLS:C0007634
27516476	1138	1153	mRNA expression	T038	UMLS:C1515670
27516476	1157	1169	adipogenesis	T038	UMLS:C0596843
27516476	1170	1179	regulator	T038	UMLS:C1152862
27516476	1180	1185	PPARG	T017	UMLS:C1335238
27516476	1230	1235	mtDNA	T103	UMLS:C0012929
27516476	1291	1295	NRF1	T017	UMLS:C1417846
27516476	1296	1311	mRNA expression	T038	UMLS:C1515670
27516476	1356	1360	COX2	T103	UMLS:C1565860
27516476	1363	1375	COX4 protein	T103	UMLS:C0033684
27516476	1412	1421	indicated	T033	UMLS:C1444656
27516476	1431	1444	mitochondrial	T017	UMLS:C0026237
27516476	1445	1453	function	T038	UMLS:C0007613
27516476	1473	1477	AKT2	T017	UMLS:C0812230
27516476	1478	1482	mRNA	T103	UMLS:C0035696
27516476	1527	1532	PTPN1	T017	UMLS:C1335281
27516476	1533	1537	mRNA	T103	UMLS:C0035696
27516476	1580	1598	insulin resistance	T038	UMLS:C0021655
27516476	1609	1628	insulin sensitivity	T038	UMLS:C0920563
27516476	1633	1661	homeostasis model assessment	T058	UMLS:C1829779
27516476	1663	1670	HOMA-IR	T058	UMLS:C1829779
27516476	1677	1686	unchanged	T033	UMLS:C0442739
27516476	1702	1704	PI	T103	UMLS:C0033607
27516476	1712	1715	ART	T058	UMLS:C1963724
27516476	1742	1745	SAT	T017	UMLS:C0222331
27516476	1746	1754	toxicity	T037	UMLS:C0600688
27516476	1846	1859	lipodystrophy	T038	UMLS:C0023787